https://scholars.lib.ntu.edu.tw/handle/123456789/548345
標題: | Thrombospondin-2 is a Highly Specific Diagnostic Marker and is Associated with Prognosis in Pancreatic Cancer | 作者: | Peng H.-Y. MING-CHU CHANG Hu C.-M. Yang H.-I. Lee W.-H. YU-TING CHANG |
公開日期: | 2019 | 出版社: | Springer New York LLC | 卷: | 26 | 期: | 3 | 起(迄)頁: | 807-814 | 來源出版物: | Annals of Surgical Oncology | 摘要: | Background: Thrombospondin-2 (TSP-2) has been reported as an early diagnostic marker for pancreatic ductal adenocarcinoma (PDAC) in Caucasian populations. This study was designed to validateTSP-2 as a diagnostic marker in a large Taiwan cohort and to investigate the association of TSP-2 with the clinical outcomes of PDAC patients. Methods: The serum TSP-2 levels in 263 PDAC patients and 230 high-risk individuals (HRIs) were measured via an enzyme-linked immunosorbent assay. The sensitivity, specificity, and accuracy of TSP-2 as a diagnostic marker to discriminating PDAC patients from HRIs and correlations between TSP-2 levels and prognosis of PDAC patients were analyzed. Results: Serum TSP-2 levels were significantly higher in patients with PDAC (44.90 ± 40.70?ng/ml) than in the HRIs (17.52 ± 6.23?ng/ml). At a level of ? 29.8?ng/ml, TSP-2 exhibited 100% specificity, 55.9% sensitivity, 100% positive predictive value (PPV), and 66.5% negative predictive value (NPV) for discriminating PDAC patients from HRIs. The Cox regression analysis showed that higher serum TSP-2 levels were significantly associated with poor outcomes in PDAC patients (hazard ratio = 1.54, 95% confidence interval = 1.143–2.086, P = 0.005). Combining the carbohydrate antigen 19-9 (CA19-9) (cutoff value of 62.0 U/ml) and TSP-2 (cutoff value of 29.8?ng/ml) levels yielded 98.7% specificity, 90.5% sensitivity, 98.8% PPV, and 90.1% NPV for discriminating patients with PDAC from HRIs. Conclusions: TSP-2 is a highly specific diagnostic marker and an independent prognostic marker in patients with PDAC. A combined biomarker panel, including TSP-2 and CA19-9, may facilitate future PDAC screening. ? 2018, Society of Surgical Oncology. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85058856755&doi=10.1245%2fs10434-018-07109-6&partnerID=40&md5=0cda4675a5fae140510d2273e8f68e01 https://scholars.lib.ntu.edu.tw/handle/123456789/548345 |
ISSN: | 1068-9265 | DOI: | 10.1245/s10434-018-07109-6 | SDG/關鍵字: | CA 19-9 antigen; thrombospondin 2; thrombospondin; thrombospondin 2; tumor marker; adult; Article; cancer patient; cancer prognosis; Caucasian; clinical outcome; cohort analysis; diagnostic accuracy; diagnostic test accuracy study; enzyme linked immunosorbent assay; female; high risk patient; human; major clinical study; male; middle aged; pancreas adenocarcinoma; predictive value; sensitivity and specificity; study design; Taiwan; blood; case control study; follow up; pancreas carcinoma; pancreas tumor; prognosis; survival rate; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Case-Control Studies; Cohort Studies; Female; Follow-Up Studies; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Survival Rate; Thrombospondins |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。